| Wednesday
| Thursday | Friday
| Sunday |
| SATURDAY, DECEMBER
13, 2008 |
| 7:00-9:00 |
POSTER DISCUSSION
SESSION 7 & CONTINENTAL BREAKFAST – Ballroom B
|
| |
Her2 as a Biomarker |
701-708 |
| |
|
| 7:00-9:00 |
POSTER
SESSION 4 & CONTINENTAL BREAKFAST – Exhibit Hall
B
(#4001-4167) |
| |
|
| |
Detection and Diagnosis |
| |
Breast Imaging - Other Methods
Marrow Micrometastases
|
4001-4029
4030-4032 |
| |
|
|
| |
Tumor Cell and Molecular Biology |
| |
Biomarkers
Epigenetics
Growth Factors
Novel Models
Oncogenes/Tumor Suppressor Genes
|
4033-4045
4046-4053
4054-4059
4060
4061-4073 |
| |
|
|
| |
Risk, Epidemiology and Prevention |
|
| |
Risk Factors and Modeling
|
4074-4087
|
| |
|
|
| |
Social, Behavioral, Economic and Outreach Studies |
|
| |
Quality of Life - Supportive Care
|
4088-4099
|
| |
|
|
| |
Treatment |
|
| |
Adjuvant Chemotherapy
Antiangiogenic Therapy (Adjuvant and Metastatic)
Biological Therapy
Male Breast Cancer
Surgery
|
4100-4112
4113-4121
4122-4127
4128-4133
4134-4153 |
| |
|
|
| |
Late Acceptances |
4154-4167 |
| |
| 9:00-9:30 |
PLENARY
LECTURE 3 – Exhibit Hall D
|
| |
The role of magnetic resonance imaging in the breast cancer patient
Monica Morrow, MD, FACS
Memorial Sloan-Kettering Cancer Center
New York, NY
|
| |
|
| 9:30-11:30 |
GENERAL SESSION 5 -Exhibit
Hall D |
| |
Jessica Leung, MD, Co-Moderator
University of California San Francisco, San Francisco, CA
and
Daniel Hayes, MD, Co-Moderator
Michigan State University, Ann Arbor, MI |
| |
|
| 9:30 |
51. The UK NIHR multicentre randomised COMICE trial of MRI planning
for breast conserving treatment for breast cancer
Drew PJ, Harvey I, Hanby A, Brown S, Olivier C, Napp V, Brown J, Turnbull LW, On
behalf of Comice Trialists. Hull York Medical School, Hull, East Yorkshire, United
Kingdom; CTIU, Leeds, Yorkshire, United Kingdom; Leeds General Infirmary,
Leeds, Yorkshire, United Kingdom; Hull Royal Infirmary, Hull, United Kingdom. |
| |
| 9:45 |
52. Tumor angiogenesis imaged by optical tomography can accurately
diagnose early-stage invasive breast cancers
Zhu Q, Kane M, Tannenbaum S, Cronin E, Hegde P, Iyers M, DeFusco P,
Ardeshirpour Y, Xu C, Baccaro N, Kurtzman S, Deckers P. University of
Connecticut, Storrs, Connecticut; University of Connecticut Health Center,
Connecticut; Hartford Hospital, Connecticut. |
| |
|
| 10:00 |
53. Risk of distant recurrence using oncotype DX in postmenopausal
primary breast cancer patients treated with anastrozole or tamoxifen: a
TransATAC study
Dowsett M, Cuzick J, Wales C, Forbes J, Mallon L, Salter J, Quinn E, Bugarini R,
Baehner FL, Shak S, on behalf of the ATAC Trialists’ Group. Royal Marsden
Hospital, London, United Kingdom; Wolfson Institute for Preventive Medicine,
London, United Kingdom; Newcastle Mater Hospital, Newcastle, Australia; Royal
Infirmary, Glasgow, United Kingdom; Genomic Health Institute, Redwood, CA.
|
| |
|
| 10:15 |
54. Evaluation of microtubule associated protein Tau expression as
prognostic and predictive marker in the NSABP-B 28 randomized clinical
trial
Pusztai L, Jeong J, Gong Y, Ross JS, Kim C, Hortobagyi GN, Paik S, Symmans WF.
UT MD Anderson Cancer Center, Houston, TX; National Adjuvant Bowel and
Breast Project, Pittsburgh, PA; Albany Medical College, Albany, NY. |
| |
|
| 10:30 |
55. Metastasis-associated microtentacles are induced in detached and circulating breast tumor cells by expression of the microtubule-binding protein, Tau
Matrone M, Whipple R, Balzer E, Cho E, Yoon J, Martin S; Graduate Program in Life Sciences, University of Maryland School of Medicine, Baltimore, MD, and the Marlene and Stewart Greenebaum NCI Cancer Center.
|
| |
|
| 10:45 |
56. c-MYC amplification and correlation with patient outcome in early
stage HER2+ breast cancer from the NCCTG adjuvant intergroup trial
N9831
Perez EA, Reinholz MM, Dueck AC, Wiktor AE, Lingle WL, Davidson NE, Martino
S, Kaufman PA, Kutteh LA, Jenkins RB. Mayo Clinic, Jacksonville, FL; Mayo Clinic,
Rochester, MN; Mayo Clinic, Scottsdale, AZ; Johns Hopkins, Baltimore, MD;
Angeles Clinic & Research Inst, Santa Monica, CA; Dartmouth Hitchcock Med
Ctr, Lebanon, NH; Oncology Associates, Cedar Rapids, IA. |
| |
|
| 11:00 |
57. Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/
IL17BR and molecular grade index) for prediction of adjuvant endocrine
therapy benefit in the ABCSG 8 trial
Goetz M, Ames M, Gnant M, Filpits M, Jakesz R, Greil R, Marth C, Samonigg H,
Suman V, Safgren S, Kuffel M, Weinshilboum R, Erlander M, Ma X-J, Ingle J. Mayo
Clinic, Rochester, MN; Vienna Medical University, Vienna, Austria; Paracelsus
Private University, Salzburg, Austria; Medical University of Innsbruck, Innsbruck,
Austria; Medical University of Graz, Graz, Austria; AviaraDx, San Diego, CA. |
| |
|
| 11:15 |
58. A 6 gene molecular predictor of lapatinib related benefit: from cell
line models to clinical trials
Gray J, Das D, Spellman P, Wang N, Kuo W-L, Wyrobek A, Bhattacharya S,
Press M, Di Leo A, Ellis C, Arbushites M, Casey M, Gagnon R, Koehler M.
Lawrence Berkeley National Laboratory, Berkeley, CA; University of Southern
California, Los Angeles, CA; Sandro Pitigliani Medical Oncology Unit, Prato, Italy;
GlaxoSmithKline, Collegeville, PA. |
| |
|
| 11:30-12:00 |
AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH -
Exhibit Hall D |
| |
Supported by an educational grant from Bristol-Myers Squibb |
| |
Deconstructing Metastasis
Joan Massagué, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY |
| |
|
| 12:00-1:45 |
LUNCH [Ticket Required] –
Exhibit Hall A |
| |
|
| 12:30-1:45 |
CASE DISCUSSION 2 – Ballroom A |
| |
Jenny Chang, MD, Moderator, Baylor College of
Medicine
George Sledge, MD, Indiana University
Eric Winer, MD, Dana-Farber/Harvard Cancer Institute
Lisa Carey, MD, Univ of North Carolina at Chapel Hill
Terry Mamounas, MD, Aultman Cancer Center
Wei Yang, MD, MD Anderson Cancer Center
Richard Zellars, MD, Johns Hopkins |
| |
|
| 12:30-1:45 |
BASIC SCIENCE PANEL DISCUSSIONS - Ballroom B |
| |
Genetic changes in the stroma – yes or no?
Charlotte Kuperwasser, PhD, Moderator
Tufts University
Boston, MA
Microenvironmental changes in breast tumor progression: genetic or epigenetic?
Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
The local and systemic evolution of the tumor microenvironment without somatic mutation
Charlotte Kuperwasser, PhD
Tufts University
Boston, MA
|
| |
|
| 2:00-3:30 |
MINI-SYMPOSIUM
3– Exhibit Hall D |
| |
|
| |
New Data on Imaging
Judy Garber, MD, Co-Moderator
Dana-Farber Cancer Institute
Boston, MA
and
David Mankoff, MD, PhD, Co-Moderator
University of Washington
Seattle, WA
|
| |
|
| 2:00 |
Introduction |
| |
|
| 2:05 |
Overview of modalities and PET imaging
David Mankoff, MD, PhD
University of Washington
Seattle, WA
|
| |
|
| 2:25 |
Breast ultrasound in the screening and diagnosis of breast cancer
Wendie A. Berg, MD, PhD, FACR
Johns Hopkins Green Spring
Lutherville, MD |
| |
|
| 2:45 |
Breast MRI
Mitchell D. Schnall, MD, PhD
University of Pennsylvania
Philadelphia, PA
|
| |
|
| 3:05 |
Dynamic molecular imaging of signal transduction pathways in vivo
David R. Piwnica-Worms, MD, PhD
Washington University
St. Louis, MO |
| |
|
| 3:30-5:00 |
GENERAL SESSION 6 -Exhibit
Hall D |
| |
Patricia Ganz, MD, Co-Moderator
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA
and
Peter Ravdin, MD, PhD, Co-Moderator
UT MD Anderson Cancer Center, Houston, TX |
| |
|
| 3:30 |
61. Change in breast density as a biomarker of breast cancer risk
reduction; results from IBIS-1
Cuzick J, Warwick J, Pinney L, Warren R, Cawthorn S, Howell A, Duffy
S. Wolfson Institute of Preventive Medicine, London, United Kingdom;
Addenbrooke’s Hospital, Cambridge, United Kingdom; Frenchay Healthcare
Trust, Bristol, United Kingdom; University of Manchester, Manchester, United
Kingdom.
|
| |
|
| 3:45 |
62. Benign breast disease and breast cancer risk in young women
Ghosh K, Pankratz VS, Reynolds CA, Vierkant RA, Anderson SS, Amy C Degnim
AC, Visscher DW, Frost MH, Vachon CM, Hartmann LC. Mayo Clinic, Rochester,
MN; University of Michigan, Ann Arbor, MI.
|
| |
|
| 4:00 |
63. Expression of estrogen responsive genes in breast cancers
correlates with plasma estradiol levels in postmenopausal women
Dunbier AK, Anderson H, Ghazoui Z, Folkerd E, Smith IE, Dowsett M. Royal
Marsden Hospital, London, United Kingdom; Breakthrough Breast Cancer
Research Centre, London, United Kingdom. |
| |
|
| 4:15 |
64. Breast cancer after stopping estrogen plus progestin in
postmenopausal women in the women’s health initiative
Chlebowski RT, Kuller L, Anderson G, Mason J, Schenken R, Rajkovic A,
Stefanick M, Sarto G, Ravdin P, Prentice R. LABioMed, Torrance, CA;
University of Pittsburgh, Pittsburgh, PA; Fred Hutchinson Cancer Research
Center, Seattle, WA; Brigham & Women’s Hospital, Chestnut Hill, MA;
University of Texas Health Science Center, San Antonio, SA; Baylor College
of Medicine, Houston, TX; Stanford University, San Jose, CA; University of
Wisconsin, Madison, WI; University of Texas MD Anderson Cancer Center,
Houston, TX. |
| |
|
| 4:30 |
65. Hormone therapy use before diagnosis and breast cancer survival
in the California Teachers Study
Marshall SF, Chang E, Clarke CA, Cress R, Deapen D, Horn-Ross PL, Largent J,
Neuhausen S, Reynolds P, Templeman C, Bernstein L. University of California,
Irvine, CA; Northern California Cancer Center, Fremont, CA; Public Health
Institute, Sacramento, CA; Keck School of Medicine, University of Southern
California, Los Angeles, CA; City of Hope Comprehensive Cancer Center,
Duarte, CA. |
| |
|
| 4:45 |
66. Effect of tibolone on breast cancer recurrence: LIBERATE trial bone sub-study.
Bundred NJ, Kenemans P, Beckmann MW, Foidart J-M, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip C-H, Egberts J, Planellas Gomez JVM, el Galta R, van Os SC. Univ of Manchester, Manchester, United Kingdom; Free Univ, Amsterdam, Netherlands; Univ Clinic, Erlangen, Germany; Univ of Liege, Liege, Belgium; Medical Univ, Vienna, Austria; Karolinska Inst, Stockholm, Sweden; Univ of Turin, Turin, Italy; MD Anderson Cancer Cen, Houston; Univ Malaya, Kuala Lumpur, Malaysia; NV Organon, Oss, Netherlands.
|
| |
|
| 5:00-7:00 |
POSTER
DISCUSSION 8 & RECEPTION – Ballroom B
|
| |
Optical Imaging |
801-807 |
| |
|
|
| 5:00-7:00 |
POSTER
SESSION 5 & RECEPTION - Exhibit Hall B
(#5001-5158) |
| |
|
| |
Detection/Diagnosis |
| |
Breast Imaging - Mammography
Screening and Detection
Circulating Tumor Cells
|
5001-5003
5004-5016
5017-5031 |
| |
|
|
| |
Tumor Cell and Molecular Biology |
| |
Cell Cycle Regulation
Etiology/Carcinogenesis
Immunology and Immunotherapy
Stem/Progenitor Cells
Stromal-Epithelial Interactions
|
5032-5036
5037-5042
5043-5050
5051-5060
5061 |
| |
|
| |
Prognosis and Response Predictions |
| |
Prognostic Factors and Biomarkers - Preclinical
|
5062-5076
|
| |
|
|
| |
Risk, Epidemiology and Prevention |
| |
Prevention - Behavioral Interventions
Prevention - Nutritional Studies
Prevention - Clinical Trials
|
5077-5078
5079-5082
5083-5088 |
| |
|
|
| |
Social, Behavioral, Economic and Outreach Studies |
|
| |
Disparities and Barriers to Care
|
5089-5100 |
| |
|
|
| |
Treatment |
|
| |
Neoadjuvant Therapy
Radiation Therapy
Breast Conservation
|
5101-5123
5124-5149
5150-5158 |
| |
|
|
 |
|
|
|
Home
Registration
Schedule at a Glance
